IL186604A0 - Therapeutic combination in case of benign prostate hyperplasia - Google Patents
Therapeutic combination in case of benign prostate hyperplasiaInfo
- Publication number
- IL186604A0 IL186604A0 IL186604A IL18660407A IL186604A0 IL 186604 A0 IL186604 A0 IL 186604A0 IL 186604 A IL186604 A IL 186604A IL 18660407 A IL18660407 A IL 18660407A IL 186604 A0 IL186604 A0 IL 186604A0
- Authority
- IL
- Israel
- Prior art keywords
- case
- therapeutic combination
- benign prostate
- prostate hyperplasia
- hyperplasia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102005016981A DE102005016981A1 (de) | 2005-04-13 | 2005-04-13 | Kombination zur Therapie bei benigner Prostatahyperplasie |
PCT/EP2006/002941 WO2006108519A1 (fr) | 2005-04-13 | 2006-03-31 | Combinaison pour traiter une hyperplasie benigne de la prostate |
Publications (1)
Publication Number | Publication Date |
---|---|
IL186604A0 true IL186604A0 (en) | 2008-01-20 |
Family
ID=36608700
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL186604A IL186604A0 (en) | 2005-04-13 | 2007-10-11 | Therapeutic combination in case of benign prostate hyperplasia |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP1888075A1 (fr) |
JP (1) | JP2008535877A (fr) |
KR (1) | KR20080007252A (fr) |
CN (1) | CN101193638A (fr) |
AR (1) | AR053575A1 (fr) |
AU (1) | AU2006233567A1 (fr) |
BR (1) | BRPI0610634A2 (fr) |
CA (1) | CA2605224A1 (fr) |
CR (1) | CR9427A (fr) |
DE (1) | DE102005016981A1 (fr) |
DO (1) | DOP2006000074A (fr) |
GT (1) | GT200600145A (fr) |
IL (1) | IL186604A0 (fr) |
MA (1) | MA29683B1 (fr) |
MX (1) | MX2007012567A (fr) |
PE (1) | PE20061338A1 (fr) |
RU (1) | RU2007141518A (fr) |
SV (1) | SV2008002477A (fr) |
TN (1) | TNSN07385A1 (fr) |
TW (1) | TW200716122A (fr) |
UY (1) | UY29473A1 (fr) |
WO (1) | WO2006108519A1 (fr) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6143746A (en) * | 1994-01-21 | 2000-11-07 | Icos Corporation | Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use |
WO2007047282A1 (fr) * | 2005-10-12 | 2007-04-26 | Lilly Icos Llc | Traitement d'une hypertrophie benigne de la prostate et de symptomes dans les voies urinaires inferieures |
CA2633570A1 (fr) * | 2005-12-21 | 2007-06-28 | Pfizer Products Inc. | Combinaison pharmaceutique d'un inhibiteur de pde-5 et d'un inhibiteur de 5-alpha reductase |
MX2008016569A (es) * | 2006-07-07 | 2009-01-30 | Teva Pharma | Composiciones solidas que contienen tadalafil y al menos un portador. |
DE102007028869A1 (de) | 2007-06-22 | 2008-12-24 | Ratiopharm Gmbh | Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil |
PL2222300T3 (pl) | 2007-12-13 | 2015-02-27 | Vanda Pharmaceuticals Inc | Sposób i skład preparatu do leczenia chorób z udziałem receptorów serotoniny |
CA2709103C (fr) | 2007-12-13 | 2017-01-17 | Vanda Pharmaceuticals Inc. | Procede et composition pour traiter une affection vehiculee par alpha-adrenocepteur |
US8885621B2 (en) | 2010-04-26 | 2014-11-11 | Intel Corporation | Method, apparatus and system for switching traffic streams among multiple bands |
WO2013123965A1 (fr) * | 2012-02-20 | 2013-08-29 | Synthon Bv | Formulation pharmaceutique à dose fixe |
CN102727456B (zh) * | 2012-07-03 | 2016-06-22 | 北京科信必成医药科技发展有限公司 | 药物口腔崩解片及其制备方法 |
RU2672573C2 (ru) * | 2013-06-28 | 2018-11-16 | Ханми Фарм. Ко., Лтд. | Фармацевтический комбинированный состав капсулы, содержащий тадалафил и тамсулозин |
KR20240015735A (ko) | 2013-07-23 | 2024-02-05 | 세레니티 파마슈티컬즈 엘엘씨 | 베타-3-아드레날린 수용체 작용제와 함께 데스모프레신을 포함하는 방법 및 조성물 |
KR20150056443A (ko) * | 2013-11-15 | 2015-05-26 | 한미약품 주식회사 | 타다라필 및 암로디핀을 포함하는 복합제제 |
EP3150201B1 (fr) * | 2014-06-30 | 2020-02-19 | Hanmi Pharm. Co., Ltd. | Preparation composite comprenant une couche de revêtement pelliculaire contenant un inhibiteur de la 5-alpha-réductase, et procédé pour produire la préparation composite |
WO2016003180A1 (fr) * | 2014-06-30 | 2016-01-07 | 한미약품 주식회사 | Preparation composite comprenant une couche de revêtement pelliculaire contenant un inhibiteur de la 5-alpha-réductase, et procédé pour produire la préparation composite |
BR112016030731A2 (pt) * | 2014-06-30 | 2017-08-22 | Hanmi Pharm Ind Co Ltd | Preparação de compósito, e, método de preparação de uma preparação de compósito |
KR20240010751A (ko) * | 2014-11-20 | 2024-01-24 | 세레니티 파마슈티컬즈 엘엘씨 | 알파-아드레날린성 수용체 길항제와 조합된 데스모프레신을 포함하는 방법 및 조성물 |
US20190125685A1 (en) * | 2016-03-31 | 2019-05-02 | Hanmi Pharm. Co., Ltd. | Composite capsule preparation containing tadalafil and tamsulosin and having improved stability and elution rate |
KR101835506B1 (ko) * | 2016-10-25 | 2018-03-07 | 주식회사 에스텍파마 | 두타스테리드와 타다라필을 함유하는 속효성 복합정제 |
CN108066347B (zh) * | 2016-11-16 | 2021-02-02 | 深圳万和制药有限公司 | 包含坦索罗辛和度他雄胺的口腔崩解片药物组合物 |
KR101879133B1 (ko) * | 2017-07-11 | 2018-07-17 | (주)동구바이오제약 | 비뇨기 질환 예방 또는 치료용 제제 및 이의 제조방법 |
TR201715231A2 (tr) * | 2017-10-09 | 2019-04-22 | Montero Gida Sanayi Ve Ticaret Anonim Sirketi | Dapokseti̇n ve fosfodi̇esteraz ti̇p-5 i̇nhi̇bi̇törü i̇çeren farmasöti̇k kombi̇nasyon |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050042177A1 (en) * | 2003-07-23 | 2005-02-24 | Elan Pharma International Ltd. | Novel compositions of sildenafil free base |
-
2005
- 2005-04-13 DE DE102005016981A patent/DE102005016981A1/de not_active Withdrawn
-
2006
- 2006-03-29 DO DO2006000074A patent/DOP2006000074A/es unknown
- 2006-03-31 JP JP2008505765A patent/JP2008535877A/ja active Pending
- 2006-03-31 WO PCT/EP2006/002941 patent/WO2006108519A1/fr active Application Filing
- 2006-03-31 RU RU2007141518/15A patent/RU2007141518A/ru unknown
- 2006-03-31 AU AU2006233567A patent/AU2006233567A1/en not_active Abandoned
- 2006-03-31 KR KR1020077026260A patent/KR20080007252A/ko not_active Application Discontinuation
- 2006-03-31 MX MX2007012567A patent/MX2007012567A/es not_active Application Discontinuation
- 2006-03-31 CN CNA2006800207814A patent/CN101193638A/zh active Pending
- 2006-03-31 CA CA002605224A patent/CA2605224A1/fr not_active Abandoned
- 2006-03-31 EP EP06723901A patent/EP1888075A1/fr not_active Withdrawn
- 2006-03-31 BR BRPI0610634-0A patent/BRPI0610634A2/pt not_active Application Discontinuation
- 2006-04-07 SV SV2006002477A patent/SV2008002477A/es not_active Application Discontinuation
- 2006-04-10 GT GT200600145A patent/GT200600145A/es unknown
- 2006-04-11 AR ARP060101410A patent/AR053575A1/es unknown
- 2006-04-11 PE PE2006000383A patent/PE20061338A1/es not_active Application Discontinuation
- 2006-04-12 UY UY29473A patent/UY29473A1/es not_active Application Discontinuation
- 2006-04-12 TW TW095112920A patent/TW200716122A/zh unknown
-
2007
- 2007-10-09 CR CR9427A patent/CR9427A/es not_active Application Discontinuation
- 2007-10-11 TN TNP2007000385A patent/TNSN07385A1/en unknown
- 2007-10-11 IL IL186604A patent/IL186604A0/en unknown
- 2007-10-29 MA MA30335A patent/MA29683B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
AR053575A1 (es) | 2007-05-09 |
GT200600145A (es) | 2007-04-10 |
MX2007012567A (es) | 2007-12-10 |
EP1888075A1 (fr) | 2008-02-20 |
RU2007141518A (ru) | 2009-05-20 |
MA29683B1 (fr) | 2008-08-01 |
TW200716122A (en) | 2007-05-01 |
DE102005016981A1 (de) | 2006-10-19 |
DOP2006000074A (es) | 2006-10-15 |
SV2008002477A (es) | 2008-02-08 |
AU2006233567A1 (en) | 2006-10-19 |
PE20061338A1 (es) | 2007-01-28 |
BRPI0610634A2 (pt) | 2010-07-13 |
TNSN07385A1 (en) | 2009-03-17 |
WO2006108519A1 (fr) | 2006-10-19 |
CN101193638A (zh) | 2008-06-04 |
UY29473A1 (es) | 2006-11-30 |
CR9427A (es) | 2007-12-17 |
CA2605224A1 (fr) | 2006-10-19 |
KR20080007252A (ko) | 2008-01-17 |
JP2008535877A (ja) | 2008-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL186604A0 (en) | Therapeutic combination in case of benign prostate hyperplasia | |
EP1959855A4 (fr) | Traitement d'une hypertrophie benigne de la prostate au moyen d'un photosensibilisant et de l'ablation laser | |
IL182533A0 (en) | Prostate treatment stent | |
IL181608A0 (en) | Cancer combination therapy comprising azd2171 and imatinib | |
HK1199874A1 (en) | Spiro-oxindole compounds and their uses as therapeutic agents | |
EP1887976B8 (fr) | Dispositifs de traitement de l'hyperplasie prostatique benigne et d'autres troubles | |
HK1215683A1 (zh) | 抗葉酸藥在癌症治療中的聯合應用 | |
HK1136822A1 (en) | Therapeutic compounds and their use in cancer | |
IL191072A0 (en) | Therapeutic compositions and methods | |
IL186615A0 (en) | Spiroheterocylic compounds and their uses as therapeutic agents | |
IL188430A0 (en) | Treatment of tumors | |
SI2275103T1 (sl) | mTor inhibitorji pri zdravljenju endokrinih tumorjev | |
IL169685A0 (en) | Treatment of benign prostatic hyperplasia using energolytic agents | |
PL2559439T3 (pl) | Preparat farmaceutyczny do leczenia łagodnego rozrostu gruczołu krokowego | |
EP2025347A4 (fr) | Agent prophylactique et thérapeutique contre le cancer | |
EP1756166A4 (fr) | Diagnostic et traitement du cancer de la prostate | |
EP2083840A4 (fr) | Traitement amélioré d'une hyperplasie bénigne de la prostate | |
ZA200709542B (en) | Combination therapy in the treatment of cancer | |
EP1904088A4 (fr) | Compositions et methodes de traitement du cancer | |
IL194463A0 (en) | Agent for the prevention and treatment of prostatic hyperplasia comprising pyrazolopyrimidinone compound | |
IL185575A0 (en) | Benzoxazocines and their therapeutic use | |
GB0301016D0 (en) | Treatment of benign prostatic hyperplasia | |
IL178303A0 (en) | Pharmaceutical composition for treating hair loss and benign prostatic hyperplasia | |
ZA200702220B (en) | Cancer combination therapy comprising AZD2171 and imatinib | |
GB0805741D0 (en) | Prophylactic and therapeutic agents and uses therefor |